Search results
Results from the WOW.Com Content Network
[28] [29] In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. [28] [30] During its development the drug was known as BMS-562247-01. [31] By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue. [32]
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...
Common side effects include nausea, dry mouth, diarrhea, constipation, vomiting (3-6% of people), and sexual dysfunction. [15] [11] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH. [15] A withdrawal syndrome may occur if the medication is abruptly stopped or the dose is ...
The diabetes treatments Jardiance from Eli Lilly and Co. and Merck's Januvia made the list, along with Amgen’s autoimmune disease treatment Enbrel. Other drugs include Entresto from Novartis ...
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [2] It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. [2]
The drugmaker is relying on newer treatments like Opdivo Qvantig to drive growth as patents on older drugs, such as cancer drug Revlimid and blood thinner Eliquis, expire later this decade.
In August 1988, the FDA approved minoxidil for treating baldness in men [48] [52] under the brand name "Rogaine" (FDA rejected Upjohn's first choice, Regain, as misleading [53]). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head". [ 53 ] "